Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-5.56% $5.10
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 66.37 mill |
EPS: | -0.450 |
P/E: | -11.33 |
Earnings Date: | Jan 26, 2024 |
SharesOutstanding: | 13.01 mill |
Avg Daily Volume: | 0.0042 mill |
RATING 2024-04-24 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -11.33 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.24x |
Company: PE -11.33 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0846 (-98.34%) $-5.02 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 4.47 - 5.73 ( +/- 12.35%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2018-02-28 | Anschutz Philip F | Sell | 12 440 000 | CLASS A COMMON STOCK |
2018-02-28 | Anschutz Philip F | Sell | 23 708 639 | CLASS B COMMON STOCK |
2018-02-28 | Campbell Michael L | Sell | 703 660 | Class A Common Stock |
2018-02-28 | Yemenidjian Alex | Sell | 21 880 | Class A Common Stock |
2018-02-28 | Tyrrell Jack | Sell | 136 684 | Class A Common Stock |
INSIDER POWER |
---|
0.00 |
Last 97 transactions |
Buy: 583 544 | Sell: 71 137 085 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.10 (-5.56% ) |
Volume | 0.0026 mill |
Avg. Vol. | 0.0042 mill |
% of Avg. Vol | 63.08 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.